
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Selection of a product formulated without alcoholis recommended to maximize efficacy of topical corticosteroid treatmentin Asian patients